CXCL8 and melanoma: H3Cit, a biomarker of NETs, predicts the risk of mortality in patients with cancer [38, 39], and elevated baseline serum IL-8 and CRP levels were associated with adverse outcomes in melanoma, NSCLC, and RCC [40].